Definitive Contract 75N93019C00006
Award Date
5/31/19
Potential Completion Date
5/30/21
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Zymeron Corporation, a minority-owned small business, to complete Phase II tasks for a Small Business Innovation Research (SBIR) program topic. The contract supports Zymeron's research and development of technologies focused on areas like protein degradation, antibacterials, antivirals, and drug delivery...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
Zymeron Corporation was awarded a $400,000 firm fixed price definitive contract by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to develop user-friendly technologies and devices to create an at-home Hepatitis C virus test under the Small Business Innovation Research Program Topic 441. As a small business concern, Zymeron will conduct the research and development effort at its facilities in Research Triangle Park, North Carolina through...
This SBIR Phase I contract from the National Institutes of Health and National Institute of Allergy and Infectious Diseases aims to develop a novel HIV vaccine co-delivery system. Zymeron Corporation will receive $300,000 to create an injectable thermosensitive hydrogel encapsulating polyroxatane-based self-amplifying RNA nanoparticles and GM-CSF cytokine adjuvant for targeted delivery. The research will take place in Research Triangle Park, North Carolina over approximately 22 months. This...
This is a $299,998.00 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) program. The contract is for Phase I research and development related to "Combinatory Treatment Modalities Utilizing Radiation to Locally Activate or Release Systemically Delivered Therapeutics", as part of SBIR Topic...
Zymeron Corporation has been awarded a $300,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to deliver an orodispersible film formulation of a second line drug for pediatric tuberculosis treatment. The contract is set aside for total small businesses and will be completed by August 31, 2022. Performance will take place in Durham, North Carolina. This award supports the National Institute of Allergy and...